Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Q2 results

- PMLiVE

Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops

Disruption to uptake of HIV and hepatitis C drugs caused by pandemic

AstraZeneca AZ

AstraZeneca escapes pandemic impact as new drugs bolster revenues

Earnings climbed above expectations in the second quarter

Roche Basel Switzerland

Roche cites COVID-19 and biosimilars in Q2 decline

Pharmaceutical sales took a 4% hit in Swiss francs

- PMLiVE

Biogen raises full year guidance after beating Q2 expectations

Key drug franchises boost total revenues in the quarter

- PMLiVE

Novartis stumbles in Q2 as COVID-19 impacts sales

Net profit drops by 4% as pandemic hits sales

- PMLiVE

Merck, Bayer flesh out vericiguat heart failure data at ACC

Drug reduced rate of cardiovascular deaths and hospitalisations

Bayer symbol

Bayer bulks up in women’s health again with non-hormonal contraceptive deal

If approved candidate would become a first-in-category therapy

Bayer symbol

Bayer extends alliance with Evotec in women’s health

Five-year research agreement focuses on polycystic ovary syndrome

- PMLiVE

Keytruda doesn’t extend survival in small cell lung cancer

Unlikely to extend use into the first-line setting

- PMLiVE

AZ, Merck’s Lynparza narrowly scores FDA approval for pancreatic cancer

Committee voted seven to five in favour of PARP inhibitor

- PMLiVE

Merck’s Keytruda significantly extends life in some prostate cancer patients

Pivotal study identifies group of 'super responders'

- PMLiVE

Merck acquires pre-clinical biotech Calporta for up to $576m

Expands into early-stage neurodegeneration research field

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links